Price T Rowe Associates Inc Intra Cellular Therapies, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ITCI
# of Institutions
381Shares Held
77.7MCall Options Held
1.7MPut Options Held
1.13M-
Vanguard Group Inc Valley Forge, PA9.23MShares$632 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.08MShares$554 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$264 Million1.4% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.82MShares$193 Million3.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.48MShares$170 Million2.06% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $6.47B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...